PhaseBio Pharmaceuticals Common Stock

PhaseBio Pharmaceuticals posts a common stock of $50K as of June 2022. That compares with $48K in the prior-year period — up 4.2% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, PhaseBio Pharmaceuticals's common stock was $48K. The latest reading is $50K — a 4.2% year-over-year increase (period ending June 2022). Use the history and growth charts on this page for a longer lookback.

Common Stock is one piece of PhaseBio Pharmaceuticals's financial statement story. At $50K, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for PHAS's common stock usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; PhaseBio Pharmaceuticals's other metric pages and overview cover the third.

Judging PhaseBio Pharmaceuticals against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in common stock easier to interpret. Start with $50K here, then scan peer and history charts to see if the gap is persistent.